Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 9/20 | 0.46 |
| ▸ | GART | P22102 | 2/20 | 0.46 |
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076811 | 0.91 | TYMS (0.65) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL8003250 | 0.91 | TYMS (0.65) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL9853745 | 0.90 | TYMS (0.71) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL2577686 | 0.89 | TYMS (0.70) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL30293737 | 0.89 | TYMS (0.70) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL440460 | 0.89 | TYMS (0.70) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL7758365 | 0.88 | TYMS (0.68) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL8375155 | 0.88 | TYMS (0.68) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL30887631 | 0.88 | TYMS (0.68) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL17732194 | 0.87 | TYMS (0.67) | TYMSKDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861514-B2 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6528631-B1 | Folates are conjugated to an oligonucleotide including at the 2'-, 3'-, 5'-, nucleobase and internucleotide linkage sites; improved transfer across cellular membranes; regioselective synthesis | ISIS PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| US-6335434-B1 | FOR INCREASED MEMBRANE PERMEABILITY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC., | 2002-01-01 | — | — | US | disclosed |
| WO-1999066063-A9 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999066063-A2 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | MTHFD1, DHFR, FOLR1 | TYMS 9/4885KDM4E 3493/4885MEN1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.